大鼠卡氏肺孢子虫肺炎黄芩苷治疗效果评价

目的 研究黄芩苷治疗大鼠卡氏肺孢子虫肺炎(PCP)的疗效。方法 以每周2次连续6周皮下注射地塞米松3.5mg/只,建立清洁级SD大鼠PCP动物模型,用黄芩苷100,200和400mg/kg灌胃,连续2周治疗实验大鼠,同时设复方新诺明治疗对照组、PCP模型对照组和正常对照组;通过各组大鼠肺重、肺重/体重比、包囊计数和肺组织病理学变化等指标评价疗效。结果 黄芩苷低(100mg/kg)、中(200mg/kg)、高(400mg/kg)剂量组大鼠肺重分别为(2.26±0.14),(1.79±0.11),(1.57±0.14)g,低于PCP模型对照组的(2.70±0.15)g(P<0.01);肺重/体重比分别为(1.32±0.22)%,(1.04±0.13)%,(0.59±0.11)%,低于PCP模型对照组的(1.98±0.18)%(P<0.01);包囊均数分别为(42.86±5.01),(41.86±6.64),(30.29±4.72),低于PCP模型对照组的(56.29±5.82)(P<0.01);肺组织炎症明显减轻,黄芩苷高剂量组与复方新诺明治疗对照组效果接近。结论 黄芩苷对大鼠卡氏肺孢子虫肺炎有明显的治疗作用,治疗效果接近复方新诺明。

Application of baicalin in treatment of Pneumocystis carinii pneumonia in rats

Objective To study the therapeutic effect of baicalin (Bai) on Pneumocystis carinii pneumonia(PCP)in rats.Methods PCP rat model was established by subcutaneous injection with dexamethasone sodium phosphate at a dose of 3.5 mg per rat,twice a week for 6 weeks.The PCP rats were orally administered with Bai at low dose ( 100 mg/kg),moderate dose(200 mg/kg )and high dose(400 mg/kg) once a day for 2 weeks.The therapy control group was orally administered with sulfamethoxazol(SMZ)250 mg/kg+trimethoprim (TMP)50mg/...